Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for chronic antibody-mediated rejection of kidney allograft
jRCTs031180443Completed
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of tocilizumab in Chronic antibody-mediated rejection of kidney transplant (cABMR). Primary endpoint: Allograft function at 1 year. Started Apr 2018; status: completed.
02
Drugs
tocilizumab
03
Conditions
Chronic antibody-mediated rejection of kidney transplant (cABMR)
Beyond the preview
Go deeper on jRCTs031180443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180443.